PMID- 21739457
OWN - NLM
STAT- MEDLINE
DCOM- 20120123
LR  - 20151119
IS  - 1096-9071 (Electronic)
IS  - 0146-6615 (Linking)
VI  - 83
IP  - 9
DP  - 2011 Sep
TI  - Molecular and clinical effects of betamethasone in human T-cell lymphotropic 
      virus type-I-associated myelopathy/tropical spastic paraparesis patients.
PG  - 1641-9
LID - 10.1002/jmv.22131 [doi]
AB  - There is no effective therapy for human T-cell lymphotropic virus type I 
      (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP). 
      Glucocorticoids are effective to reduce the motor disability in these patients, 
      but its role as anti-spastic drugs is unknown. Here it is reported the use of 
      corticosteroids in HAM/TSP. The goal was to find reliable molecular markers 
      linked to treatment effectiveness. The clinical efficacy of corticosteroids was 
      studied in 22 HAM/TSP. The treatment was a single dose of 7.0 mg of systemic 
      betamethasone. Pre-treatment samples were obtained immediately before steroid 
      administration and post-treatment samples were collected after 5 days. 
      Neurological disability was evaluated by the Osame's Motor Disability Scales. 
      Relative levels of Tax, Foxp3, IL-10, TGF-beta, CTLA-4, and GITR mRNA were measured 
      and the percentage of CD4(+) Foxp3(+) and CD4(+) Tax(+) populations was 
      quantified in PBMCs by real-time PCR and flow cytometry, respectively. The same 
      parameters were studied in eight untreated carriers. Betamethasone treatment 
      showed neurological improvement in 21 HAM/TSP patients, with one patient without 
      response to treatment. This therapy was associated with a decrease in Tax mRNA 
      load and CD4(+) Tax(+) T cells in HAM/TSP. Simultaneously, an increase in Foxp3 
      mRNA and CD4(+) Foxp3(+) T cell was detected in these patients. The other markers 
      studied had no significant changes after treatment. Clinical improvement in 
      betamethasone-treated HAM/TSP was associated with an inverse relationship between 
      a decrease in Tax and an increase in Foxp3 at the mRNA and protein levels. These 
      results suggest that both Tax and Foxp3 may represent potential biomarkers for 
      drug treatment assessments in HAM/TSP.
CI  - Copyright (c) 2011 Wiley-Liss, Inc.
FAU - Alberti, Carolina
AU  - Alberti C
AD  - Faculty of Chemical and Pharmaceutical Sciences, Department of Biochemistry and 
      Molecular Biology, University of Chile, Santiago, Chile.
FAU - Cartier, Luis
AU  - Cartier L
FAU - Valenzuela, Maria A
AU  - Valenzuela MA
FAU - Puente, Javier
AU  - Puente J
FAU - Tanaka, Yuetsu
AU  - Tanaka Y
FAU - Ramirez, Eugenio
AU  - Ramirez E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Med Virol
JT  - Journal of medical virology
JID - 7705876
RN  - 0 (Antigens, CD)
RN  - 0 (Biomarkers)
RN  - 0 (Cytokines)
RN  - 0 (FOXP3 protein, human)
RN  - 0 (Forkhead Transcription Factors)
RN  - 0 (Gene Products, tax)
RN  - 0 (RNA, Messenger)
RN  - 9842X06Q6M (Betamethasone)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antigens, CD/blood
MH  - Betamethasone/administration & dosage/*therapeutic use
MH  - Biomarkers/blood
MH  - CD4-Positive T-Lymphocytes/virology
MH  - Cytokines/blood
MH  - Female
MH  - Flow Cytometry
MH  - Forkhead Transcription Factors/*blood
MH  - Gene Products, tax/*blood/genetics
MH  - *Human T-lymphotropic virus 1/drug effects/genetics/physiology
MH  - Humans
MH  - Leukocytes, Mononuclear
MH  - Lymphocyte Count
MH  - Male
MH  - Middle Aged
MH  - Paraparesis, Tropical Spastic/*drug therapy/virology
MH  - Polymerase Chain Reaction
MH  - RNA, Messenger
MH  - Viral Load
EDAT- 2011/07/09 06:00
MHDA- 2012/01/24 06:00
CRDT- 2011/07/09 06:00
PHST- 2011/07/09 06:00 [entrez]
PHST- 2011/07/09 06:00 [pubmed]
PHST- 2012/01/24 06:00 [medline]
AID - 10.1002/jmv.22131 [doi]
PST - ppublish
SO  - J Med Virol. 2011 Sep;83(9):1641-9. doi: 10.1002/jmv.22131.